344 related articles for article (PubMed ID: 34558835)
1. Ipragliflozin Improves the Hepatic Outcomes of Patients With Diabetes with NAFLD.
Takahashi H; Kessoku T; Kawanaka M; Nonaka M; Hyogo H; Fujii H; Nakajima T; Imajo K; Tanaka K; Kubotsu Y; Isoda H; Oeda S; Kurai O; Yoneda M; Ono M; Kitajima Y; Tajiri R; Takamori A; Kawaguchi A; Aishima S; Kage M; Nakajima A; Eguchi Y; Anzai K
Hepatol Commun; 2022 Jan; 6(1):120-132. PubMed ID: 34558835
[TBL] [Abstract][Full Text] [Related]
2. Comparison of Ipragliflozin and Pioglitazone Effects on Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Randomized, 24-Week, Open-Label, Active-Controlled Trial.
Ito D; Shimizu S; Inoue K; Saito D; Yanagisawa M; Inukai K; Akiyama Y; Morimoto Y; Noda M; Shimada A
Diabetes Care; 2017 Oct; 40(10):1364-1372. PubMed ID: 28751548
[TBL] [Abstract][Full Text] [Related]
3. The Selective SGLT2 Inhibitor Ipragliflozin Has a Therapeutic Effect on Nonalcoholic Steatohepatitis in Mice.
Honda Y; Imajo K; Kato T; Kessoku T; Ogawa Y; Tomeno W; Kato S; Mawatari H; Fujita K; Yoneda M; Saito S; Nakajima A
PLoS One; 2016; 11(1):e0146337. PubMed ID: 26731267
[TBL] [Abstract][Full Text] [Related]
4. SGLT2 inhibitor ipragliflozin alone and combined with pioglitazone prevents progression of nonalcoholic steatohepatitis in a type 2 diabetes rodent model.
Tahara A; Takasu T
Physiol Rep; 2019 Nov; 7(22):e14286. PubMed ID: 31782258
[TBL] [Abstract][Full Text] [Related]
5. Empagliflozin for the Treatment of Nonalcoholic Steatohepatitis in Patients with Type 2 Diabetes Mellitus.
Lai LL; Vethakkan SR; Nik Mustapha NR; Mahadeva S; Chan WK
Dig Dis Sci; 2020 Feb; 65(2):623-631. PubMed ID: 30684076
[TBL] [Abstract][Full Text] [Related]
6. Ipragliflozin Improves Hepatic Steatosis in Obese Mice and Liver Dysfunction in Type 2 Diabetic Patients Irrespective of Body Weight Reduction.
Komiya C; Tsuchiya K; Shiba K; Miyachi Y; Furuke S; Shimazu N; Yamaguchi S; Kanno K; Ogawa Y
PLoS One; 2016; 11(3):e0151511. PubMed ID: 26977813
[TBL] [Abstract][Full Text] [Related]
7. Rationale and design of a multicenter randomized controlled study to evaluate the preventive effect of ipragliflozin on carotid atherosclerosis: the PROTECT study.
Tanaka A; Murohara T; Taguchi I; Eguchi K; Suzuki M; Kitakaze M; Sato Y; Ishizu T; Higashi Y; Yamada H; Nanasato M; Shimabukuro M; Teragawa H; Ueda S; Kodera S; Matsuhisa M; Kadokami T; Kario K; Nishio Y; Inoue T; Maemura K; Oyama J; Ohishi M; Sata M; Tomiyama H; Node K;
Cardiovasc Diabetol; 2016 Sep; 15(1):133. PubMed ID: 27619983
[TBL] [Abstract][Full Text] [Related]
8. Ipragliflozin, a sodium-glucose cotransporter 2 inhibitor, reduces bodyweight and fat mass, but not muscle mass, in Japanese type 2 diabetes patients treated with insulin: A randomized clinical trial.
Inoue H; Morino K; Ugi S; Tanaka-Mizuno S; Fuse K; Miyazawa I; Kondo K; Sato D; Ohashi N; Ida S; Sekine O; Yoshimura M; Murata K; Miura K; Arima H; Maegawa H;
J Diabetes Investig; 2019 Jul; 10(4):1012-1021. PubMed ID: 30536746
[TBL] [Abstract][Full Text] [Related]
9. Impact of body mass index on the efficacy and safety of ipragliflozin in Japanese patients with type 2 diabetes mellitus: A subgroup analysis of 3-month interim results from the Specified Drug Use Results Survey of Ipragliflozin Treatment in Type 2 Diabetic Patients: Long-term Use study.
Tobe K; Maegawa H; Tabuchi H; Nakamura I; Uno S
J Diabetes Investig; 2019 Sep; 10(5):1262-1271. PubMed ID: 30719865
[TBL] [Abstract][Full Text] [Related]
10. Favorable effect of sodium-glucose cotransporter 2 inhibitor, dapagliflozin, on non-alcoholic fatty liver disease compared with pioglitazone.
Cho KY; Nakamura A; Omori K; Takase T; Miya A; Yamamoto K; Nomoto H; Kameda H; Taneda S; Kurihara Y; Aoki S; Atsumi T; Miyoshi H
J Diabetes Investig; 2021 Jul; 12(7):1272-1277. PubMed ID: 33131199
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of sodium-glucose cotransporter 2 inhibitor ipragliflozin on glycemic control and cardiovascular parameters in Japanese patients with type 2 diabetes mellitus; Fukuoka Study of Ipragliflozin (FUSION).
Nomiyama T; Shimono D; Horikawa T; Fujimura Y; Ohsako T; Terawaki Y; Fukuda T; Motonaga R; Tanabe M; Yanase T;
Endocr J; 2018 Aug; 65(8):859-867. PubMed ID: 29806620
[TBL] [Abstract][Full Text] [Related]
12. Ipragliflozin, an SGLT2 inhibitor, exhibits a prophylactic effect on hepatic steatosis and fibrosis induced by choline-deficient l-amino acid-defined diet in rats.
Hayashizaki-Someya Y; Kurosaki E; Takasu T; Mitori H; Yamazaki S; Koide K; Takakura S
Eur J Pharmacol; 2015 May; 754():19-24. PubMed ID: 25701721
[TBL] [Abstract][Full Text] [Related]
13. Amelioration of fatty liver index in patients with type 2 diabetes on ipragliflozin: an association with glucose-lowering effects.
Takase T; Nakamura A; Miyoshi H; Yamamoto C; Atsumi T
Endocr J; 2017 Mar; 64(3):363-367. PubMed ID: 27980239
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the effects of three kinds of glucose-lowering drugs on non-alcoholic fatty liver disease in patients with type 2 diabetes: A randomized, open-label, three-arm, active control study.
Kinoshita T; Shimoda M; Nakashima K; Fushimi Y; Hirata Y; Tanabe A; Tatsumi F; Hirukawa H; Sanada J; Kohara K; Irie S; Kimura T; Nakamura Y; Nishioka M; Obata A; Nakanishi S; Mune T; Kaku K; Kaneto H
J Diabetes Investig; 2020 Nov; 11(6):1612-1622. PubMed ID: 32329963
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of Ipragliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor, as a Second-line Treatment for Non-Alcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus Who Do Not Respond to Incretin-Based Therapies Including Glucagon-like Peptide-1 Analogs and Dipeptidyl Peptidase-4 Inhibitors.
Ohki T; Isogawa A; Toda N; Tagawa K
Clin Drug Investig; 2016 Apr; 36(4):313-9. PubMed ID: 26914659
[TBL] [Abstract][Full Text] [Related]
16. Rationale and design of an investigator-initiated, multicenter, prospective open-label, randomized trial to evaluate the effect of ipragliflozin on endothelial dysfunction in type 2 diabetes and chronic kidney disease: the PROCEED trial.
Tanaka A; Shimabukuro M; Okada Y; Sugimoto K; Kurozumi A; Torimoto K; Hirai H; Node K;
Cardiovasc Diabetol; 2020 Jun; 19(1):85. PubMed ID: 32534578
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic Effects of SGLT2 Inhibitor Ipragliflozin and Metformin on NASH in Type 2 Diabetic Mice.
Tahara A; Takasu T
Endocr Res; 2020; 45(2):147-161. PubMed ID: 31955626
[No Abstract] [Full Text] [Related]
18. Long-term empagliflozin therapy improves levels of hepatic fibrosis marker in patients with non-alcoholic fatty liver disease complicated by type 2 diabetes mellitus.
Shinozaki S; Tahara T; Lefor AK; Ogura M
J Med Invest; 2020; 67(3.4):280-284. PubMed ID: 33148902
[TBL] [Abstract][Full Text] [Related]
19. The Improvement of the Hepatic Histological Findings in a Patient with Non-alcoholic Steatohepatitis with Type 2 Diabetes after the Administration of the Sodium-glucose Cotransporter 2 Inhibitor Ipragliflozin.
Takeda A; Irahara A; Nakano A; Takata E; Koketsu Y; Kimata K; Senda E; Yamada H; Ichikawa K; Fujimori T; Sumida Y
Intern Med; 2017 Oct; 56(20):2739-2744. PubMed ID: 28924123
[TBL] [Abstract][Full Text] [Related]
20. Effects of newer antidiabetic drugs on nonalcoholic fatty liver and steatohepatitis: Think out of the box!
Ranjbar G; Mikhailidis DP; Sahebkar A
Metabolism; 2019 Dec; 101():154001. PubMed ID: 31672448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]